reproxalap   Click here for help

GtoPdb Ligand ID: 10613

Synonyms: ADX-102 | ADX102 | example 5 [WO2018039197A1] | NS-2 | NS2 [1]
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Reproxalap is a novel small molecule that acts as a molecular trap for pro-inflammatory Reactive Aldehyde Species (RASP) that was developed by Aldeyra Therapeutics. Reproxalap (as example 5; NS2) and its uses are claimed in Aldeyra patent WO2018039197A1 [1].
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 3
Hydrogen bond donors 2
Rotatable bonds 1
Topological polar surface area 59.14
Molecular weight 236.07
XLogP 2.27
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES Clc1ccc2c(c1)cc(c(n2)C(O)(C)C)N
Isomeric SMILES Clc1ccc2c(c1)cc(c(n2)C(O)(C)C)N
InChI InChI=1S/C12H13ClN2O/c1-12(2,16)11-9(14)6-7-5-8(13)3-4-10(7)15-11/h3-6,16H,14H2,1-2H3
InChI Key GUHFUVLKYSQIOQ-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Reproxalap (ADX-102) has advanced to phase 3 clinical evaluation in parients with allergic conjunctivitis (NCT04207736) and Sjogren-Larsson syndrome (NCT03445650). Online reports from mid-2019 indicate that reproxalap failed to meet its primary and secondary endpoints in noninfectious anterior uveitis.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03445650 RESET Trial - Part 1 (Followed by Reset Trial - Part 2) - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS) Phase 3 Interventional Aldeyra Therapeutics, Inc.
NCT04207736 The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis. Phase 3 Interventional Aldeyra Therapeutics, Inc.